Q1 FY2027 · ended Jul 31, 2026 · Revenue $0 · Filed Sep 14, 2026
Pharmacyte Biotech, Inc. (PMCB) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q1 of fiscal 2027, the quarter ended Jul 31, 2026, it reported revenue of $0 and a net loss of $5.1 million.
Revenue
$0
Net income
$-5.08M
+39.2% vs year-ago quarter
Operating cash flow
$-780,894
+60.8% vs year-ago quarter
Free cash flow
—
EPS
$-0.54
+56.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
10.74M
+58.0% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PMCB (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- NV
- Headquarters
- Las Vegas, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1157075
- Former names
- NUVILEX, INC. (until Jan 9, 2015); EFOODSAFETY COM INC (until Mar 17, 2009)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Jul 31, 2026 |
Q4 FY2026 Apr 30, 2026 |
Q3 FY2026 Jan 31, 2026 |
Q2 FY2026 Oct 31, 2025 |
Q1 FY2026 Jul 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$1.0M | -$2.5M | -$2.1M | -$1.4M | -$848,305 |
| Net income | -$5.1M | -$4.4M | $746,860 | -$7.4M | -$8.4M |
| Diluted EPS | -$0.54 | -$0.45 | -$0.17 | -$1.24 | -$1.23 |
| Operating cash flow | -$780,894 | -$1.4M | -$786,848 | -$979,523 | -$2.0M |
| Total assets | $36.7M | $46.8M | $55.9M | $56.0M | $45.1M |
| Total liabilities | $6.9M | $11.8M | $16.5M | $19.4M | $1.5M |
| Stockholders' equity | $27.5M | $33.3M | $38.1M | $35.2M | $43.6M |
| Cash and investments | $17.8M | $18.9M | $20.5M | $15.6M | $13.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Auditor change
|
Oct 16, 2026 | Oct 14, 2026 |
| 10-Q | Quarterly report | Sep 14, 2026 | Jul 31, 2026 |
| 10-K | Annual report | Jul 29, 2026 | Apr 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Apr 2, 2026 | Mar 30, 2026 |
| 10-Q | Quarterly report | Mar 17, 2026 | Jan 31, 2026 |
| ARS | Annual report to shareholders | Mar 9, 2026 | Apr 30, 2025 |
All 472 Pharmacyte Biotech, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.